Anti-COVID-19 natural products are spotlights for drug discovery and development
DOI:
https://doi.org/10.22270/ajprd.v8i4.785Keywords:
Covid-19, Natural product, phytochemical and CLpro inhibitor.Abstract
Traditional plants and marine natural products have plausible medicinal compounds of anti-COVID-19 potential. They became spotlights for the development and discovery of new marketable antivirals. The global COVID-19 pandemic invigorated medicinal chemists to evolve new feasible ideas for the non-toxic medications.
Downloads
References
2. D. C. Dinesh, S. lamilarasan, K. Rajaram, and E.Boura,̎ Antiviral Drug Targets of Single-Stranded RNA virus Causing Chronic Human Diseases,” Current drug targets, vol. 21, no.2. pp. 105-124, 2020.
3. H. Chen and Q. Du, ̎Potential natural compounds for preventing 2019-nCoV infection,” preprints. 2020
4. Ayush Sara.org – use of herbal medicines on Coronavirus vol.4 issue 4 April 2020 Acta scientific pharmaceutical Science.
5. A Reza zadeh et al- plants as prospective source of natural anti-COVID19 Compounds, April 15, 2020, doi:10.20944/preprints202004.0321.v1
6. Antonio Rescifina et.al. Inhibitors of SARS-CoV-2 Main protease from a Library of Marine Natural Products: A Virtual Screening and Molecular Modeling Study Research gate, doi:10.20944/preprints202003.0372.v1
7. Dong. S. Hu, and J. Gao,˝Discovering drugs to treat coronavirus disease 2019(COVID19),” Drug discoveries and therapeutics, vol. 14, no. 1, pp. 58-60,2020.
8. M. T. ulQamar, S. M. Alqahtani, M. A. Alamri, and L-L Chen, ̎Structural basis of SARS-CoV-2 3CLpro and anti- COVID-19 drug discovery from medicinal plants,” Journal of pharmaceutical Analysis, 2020/03/26/2020,
9. C.-N. Chen et al., ̎Inhibition of SARS-CoV 3C-like protease activity by theaflacin-3, 3’- digallate (TF3),” Evidence-Based Complementary and Alternative Medicine, vol. 2, no. 2, pp. 209-215, 2005.
10. K.Anand, H. Yang, M. Bartlam, Z. Rao, and R. Hilgenfeld, ̎Coronavirus main proteinase: target for antiviral drug therapy,” in Coronavirus with special emphasis on first insights concerning SARS: Springer, 2005, pp. 173-199.
11. N. Mohammadi and N. Shaghaghi, ̎ Inhibitory effect of eight secondary Metabolite from conventional Medicine plants on COVID 19 virus protease by Molecular Docking Analysis,” 2020.
12. C.-W. Lin et al., ̎Anti-SARS coronavirus 3C-like protease effects of Isatisindigotica root and plant-derived phenolic compounds,” Antiviral Research, vol. 68, no. l, pp. 36-42, 2005/10/01/2005,
13. C.-C. Wen et al., ̎Specific plant Terpenoids and Lignoids Possess Potent Antiviral Activities against severe Acute Respiratory Syndrome Coronavirus,” Journal of Medicinal Chemistry, vol. 50, no. 17, pp. 4087-4095, 2007/08/01 2007, doi: 10.1021/jm070295s.
14. J.-Y. Park et al., ̎Chalcones isolated from Angelica keiskei inhibit cysteine proteases of SARS-CoV,” Journal of enzyme inhibition and medicinal chemistry, vol.31, no. l, pp. 23-30, 2016.
15. Y. B. Ryu et al., ̎SARS-CoV 3CLpro inhibitory effects of quinone-methidetriterpenes from Tripterygiumregelii,” Bioorganic and medicinal chemistry letters, vol. 20, no.6, pp. 1873-1876, 2010.
16. S. Jo, S. Kim, D. H. Shin, and M.-S. Kim, ̎Inhibition of SARS-CoV 3VL, protease by flavonoids,” Journal of Enzyme Inhibition and and Medicinal Chemistry, vol.35, no. 1, pp. 145- 151, 2020/01/01 2020, doi:10.1080/14756366.2019.1690480.
17. F. Chen et al, ̎In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds,” Journal of clinical virology, vol. 31,no.1, pp.69-75,2004/09/01/2004,
18. S. Jo, S. Kim, D. H. Shin, and M.-S. Kim, ̎Inhibition of SARS-CoV 3VL, protease by flavonoids,” Journal of Enzyme Inhibition and and Medicinal Chemistry, vol.35, no. 1, pp. 145- 151, 2020/01/01 2020, doi:10.1080/14756366.2019.1690480.
19. C-30 Endopeptidases Wikipedia.
20. K.-C. Chou, D.-Q. Wei, and W.-Z. Zhong, ̎Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS,” Biochemical and biophysical research communications, vol. 308, no.l, pp. 148-151,2003.
21. Michal acceptor Pubmedncbinlmgov.
Published
How to Cite
Issue
Section
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.